CurrentBlue Cross Blue Shield - OklahomaPolicy CPCPLAB049

General Inflammation Testing (CRP and ESR)

Defines BCBS Oklahoma reimbursement stance for laboratory measurement of inflammatory markers (C-reactive protein and erythrocyte sedimentation rate) and related limits on concurrent testing; applies to providers submitting claims to BCBS OK plans. Providers should check specific plan documents for product-level differences.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyGeneral Inflammation Testing (CRP and ESR)

Policy CodePolicy CPCPLAB049

Change TypeNo material changes

Effective DateNov 1, 2022

Next Review Date

Key ActionProviders must submit accurate documentation and claims using valid HIPAA-approved codes and check product-specific plan documents for coverage differences.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

CRP or ESR reimbursableCRP or ESR reimbursable

Concurrent CRP+ESR allowed for PJIConcurrent for PJI

Concurrent disallowedConcurrent disallowed (non-PJI)

Not reimbursableNot reimbursable in general exam

ESR reimbursableESR for Hodgkin Lymphoma

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyGeneral Inflammation Testing (CRP and ESR)

Policy CodePolicy CPCPLAB049

Change TypeNo material changes

Effective DateNov 1, 2022

Next Review Date

Key ActionProviders must submit accurate documentation and claims using valid HIPAA-approved codes and check product-specific plan documents for coverage differences.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Inflammatory Marker Testing

CRP and ESR reimbursement criteria

Reimbursement Information:

ALL of the following

Measurement of erythrocyte sedimentation rate (ESR) for patients with Hodgkin Lymphoma may be reimbursable.
Measurement of either C-Reactive Protein (CRP) or ESR in the diagnosis, assessment and monitoring of inflammatory disorders, and/or undiagnosed conditions, and/or to detect acute phase inflammation may be reimbursable. See Note 1 regarding CRP as a cardiac biomarker and related policy CPCPLAB046.
See NOTE 1: CPCPLAB046 Cardiac Biomarkers for Myocardial Infarction.
Concurrent measurement of CRP and ESR may be reimbursable in the diagnosis of periprosthetic joint infections (PJI).
For any condition other than PJI, measurement of both CRP and ESR at the same visit in the diagnosis, assessment and monitoring of inflammatory disorders, and/or undiagnosed conditions, and/or to detect acute phase inflammation is not reimbursable.
Do not bill both tests together for non-PJI indications at same visit.
Measurement of either CRP and/or ESR during general exam without abnormal findings is not reimbursable.

References and Policy History

References and Policy History:

ALL of the following

References: See list below for supporting literature and guideline sources used in developing this policy.
Policy Update History:
11/1/2022 — New policy (effective date 2022-11-01).

Coding and Billing Guidance

Coding guidance (general)mixed

No CPT/HCPCS listed in this section

Policy references use of standard HIPAA-approved code sets but does not list specific test codes in provided content.

References only - no codes listedmixed

No codes listed

inv-05: Concurrent testing rule

Concurrent testing ruleConcurrent measurement of CRP and ESR may be reimbursable in the diagnosis of periprosthetic joint infections (PJI); for any condition other than PJI, measurement of both CRP and ESR at the same visit is not reimbursable.

ScopeApplies to measurement performed at the same visit for diagnosis, assessment, and monitoring of inflammatory disorders or to detect acute phase inflammation.

Product varianceNot all requirements apply to each product; providers should consult specific plan documents for product-level differences.

inv-06: No numeric thresholds provided

Numeric thresholdsNo numeric laboratory value thresholds (e.g., CRP mg/L or ESR mm/hr cutoffs) are provided in this policy.

Provider Responsibilities and Billing Notes

Documentation Required

Provider documentation and plan variance

No prior authorization is required for the laboratory tests described in this policy. Providers must submit accurate, complete documentation supporting the medical necessity of testing upon request. Claims are subject to standard code edit protocols and review; submission of additional clinical records may be requested to substantiate coverage.

No prior authorization required.
Submit supporting documentation upon request.
Claims are subject to code edit and medical necessity review.

Billing Rule

No prior authorization, billing rule, or step-therapy specified

No specific billing rules, step therapy, quantity limits, or explicit denial actions are specified in this policy. However, reimbursement is subject to product-specific lab management criteria and plan document provisions; providers should review the member's plan for coverage details. Concurrent measurement of CRP and ESR is reimbursable for periprosthetic joint infection (PJI) only; concurrent CRP and ESR for other conditions at the same visit is not reimbursable.

Definitions and Contextual Notes

inv-09: Periprosthetic joint infection (PJI) — clinical context for concurrent testing

DefinitionPeriprosthetic joint infection (PJI) — clinical context in which concurrent CRP and ESR measurement may be reimbursable for diagnosis.

Allowed testingConcurrent CRP and ESR may be reimbursable specifically when used to diagnose PJI.

Contrast with other conditionsFor conditions other than PJI, concurrent measurement of both tests at the same visit is not reimbursable.

inv-10: General exam without abnormal findings — not reimbursable

DefinitionGeneral exam without abnormal findings — routine examination where no abnormal findings are present.

Reimbursement stanceMeasurement of CRP and/or ESR during a general exam without abnormal findings is not reimbursable.